The Prevention and Treatment of Human Disease Resulting from Bacterial Infection

Syntiron LLC is dedicated to developing vaccines and immunotherapeutics to prevent and treat a wide range of life-threatening bacterial diseases and infections—diseases that threaten millions of lives and place an increasing burden on healthcare systems in both developed and emerging economies.

Our patented SRP® technology has been validated by widespread clinical and commercial veterinary trials. Our research team is using this technology to pursue a range of vaccines to fight bacterial diseases, including nosocomial (hospital-acquired) infections, food and waterborne infections, bacterial biowarfare agents, urinary tract infections (UTIs), and wound infections.

In conjunction with our strategic and research partners, including the world’s largest vaccine manufacturer, sanofi pasteur, the National Institutes of Health (NIH), and the US Defense Threat Reduction Agency (DTRA), Syntiron is developing vaccines and therapeutics with immediate commercial application for biodefense, antibiotic-resistant infections, food safety and women’s health. Current projects include:

• Hospital infections
  • MRSA (Staphylococcus aureus)
  • Pseudomonas
• Food and waterborne infections
  • Food poisoning (Salmonella spp., E. coli, Campylobacter)
  • Dysentery (Shigella spp.)
  • Diarrhea (ETEC, Vibrio cholera)
• Bacterial warfare agents
  • Plague (Yersinia pestis)
  • Anthrax (Bacillus anthracis)
  • Melioidosis (Burkholderia spp.)
• UTIs
• Wound infections